Nigeria’s pharmaceutical industry has long depended on imports, with nearly all medicines sourced from abroad. This reliance has left the country vulnerable to supply shocks, foreign exchange pressures, and inflated costs. AltBank’s unveiling of a non-interest financing initiative marks a significant intervention aimed at reshaping this landscape.
AltBank’s financing is structured around asset-backed, risk-sharing mechanisms. Unlike traditional loans, repayment obligations are tied to business cash flow, reducing the burden on manufacturers. The bank is offering products such as stock financing to help pharmacies and distributors maintain inventory, vendor and distributor financing to stabilize supply chains, revolving drug funds for continuous access to essential medicines, and supply chain financing to strengthen logistics from production to distribution. By aligning financing with operational realities, AltBank hopes to encourage investment in WHO-compliant manufacturing plants, research, and local innovation.
Africa carries a quarter of the global disease burden but produces less than three percent of its medicines. Local production is vital for sovereignty in healthcare. Reducing imports eases foreign exchange demand, creates jobs in manufacturing and logistics, and lowers drug prices. The COVID-19 pandemic exposed vulnerabilities in global supply chains, reinforcing the need for domestic capacity.
Challenges remain. Investors need assurance that government policies will remain consistent to support long-term pharmaceutical growth. Manufacturers must upgrade facilities to meet international standards, requiring significant capital. Imported drugs may remain cheaper in the short term, necessitating government incentives to level the playing field.
Other countries have pursued similar strategies. India leveraged non-interest and subsidized financing to build its generics industry, now a global leader. Bangladesh used targeted financing and policy support to achieve near self-sufficiency in essential medicines. South Africa invested in local vaccine production post-COVID, though challenges remain in scaling. Nigeria’s approach, if sustained, could mirror these successes, positioning the country as a regional pharmaceutical hub.
Pharmacists and healthcare operators have welcomed the initiative, noting that financing has been a major barrier to scaling production. Social media commentary has praised AltBank for thinking beyond profit and aligning with national health priorities. Critics caution that without strong regulatory oversight, financing alone may not guarantee quality or affordability.
